In CT26 mouse models, the combination treatment resulted in tumor regression and prolonged the mouse survival compared with single treatment or control (Fig. S6A–D) and improved Cd8+ T cell function in tumor cells and spleens compared with anti-PD-1 antibodies (Fig. S6F, G) but all mouse weights remained unchanged (Fig. S6E). Here, CD8A is linked to neoplasm.